Agency Cites Serious Violations of Federal Adverse Event Reporting Requirements for Semaglutide
Last updated: May 2026 | Warning letter date: March 5, 2026 | Drug: Ozempic / Wegovy (semaglutide) | Read time: ~9 min
In March 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk — the manufacturer of Ozempic and Wegovy — alleging that the company had committed serious violations of federal adverse event reporting requirements related to its semaglutide-based medications. The letter, dated March 5, 2026, followed an inspection of a Novo Nordisk facility in New Jersey and represents one of the most significant regulatory actions taken against the company in connection with its GLP-1 drug franchise.
The warning letter does not constitute a finding that Ozempic or Wegovy caused any specific adverse outcome. The FDA’s allegations are procedural in nature: the agency contends that Novo Nordisk failed to submit certain adverse event reports within the mandatory timeframes established under federal law, and that the company failed to adequately investigate at least one of the reported events before the reporting window closed. What the letter does establish — with considerable legal and regulatory significance — is that adverse event data the FDA is legally entitled to receive in a timely manner may not have been delivered on schedule.
This development may have direct relevance to the thousands of GLP-1 lawsuits currently pending in MDL 3094 and MDL 3163. If Novo Nordisk was not meeting its federally mandated reporting obligations, plaintiffs’ attorneys argue that the FDA’s ability to identify emerging safety signals and require label updates may have been compromised — potentially delaying warnings that patients deserved sooner.
What the FDA Alleged: The Specific Violations
FDA warning letters are carefully drafted regulatory documents that identify specific statutory and regulatory provisions the agency believes have been violated. The March 2026 letter to Novo Nordisk cited concerns centered on two distinct categories of obligation under federal pharmaceutical law.
Failure to Submit Reports Within Required Timeframes
Under 21 CFR Part 314.81, pharmaceutical manufacturers are required to report serious and unexpected adverse drug reactions to the FDA within 15 calendar days of first becoming aware of them. These are known as expedited safety reports or 15-day reports, and the timeline is mandatory — not advisory. The FDA’s inspection of the Novo Nordisk New Jersey facility identified adverse event reports involving semaglutide that the company allegedly did not submit within that required window. Three of the incidents referenced in the letter involved patient deaths, including one involving suicide.
The 15-day requirement exists for a specific regulatory reason: serious adverse events require prompt FDA review so that the agency can determine whether the accumulating safety data warrants expedited label changes, public safety communications, or other protective measures. When reports are delayed, the agency’s surveillance function is impaired — regardless of whether the individual events can ultimately be attributed to the drug.
Failure to Adequately Investigate a Reported Event
Beyond the timeline violations, the FDA also alleged that Novo Nordisk failed to conduct an adequate investigation into the suicide-related adverse event report before the reporting window closed. The federal obligation is not merely to transmit reports — it is to investigate them sufficiently to allow for a meaningful regulatory assessment of the event. An inadequately investigated report limits the FDA’s ability to evaluate the safety signal the report may represent, including whether any connection to the drug exists that would warrant further action.
The Critical Distinction: Reporting Failure vs. Causation
It is important to be precise about what the FDA’s warning letter does and does not conclude. The agency explicitly did not find that Ozempic or Wegovy caused the three patient deaths referenced in the letter, including the suicide. Adverse event reporting systems are not designed to establish causation — they are designed to collect potential safety signals, which regulators then investigate through separate analytical processes. A death reported to the FDA as a potential adverse event involving a specific drug may, upon investigation, be found to have been unrelated to that drug. The reporting obligation exists regardless of whether causation is ultimately established.
What the warning letter does conclude is that Novo Nordisk had a legal obligation to report these events within 15 days and, in at least one case, to investigate before reporting — and that the company failed to meet those obligations. The regulatory violation is the failure to comply with the reporting process, not a determination about the underlying events themselves.
The New Jersey Inspection
The FDA’s findings were based on an inspection conducted at a Novo Nordisk facility in New Jersey — the state where the company maintains its U.S. headquarters in Plainsboro. FDA inspections of pharmaceutical manufacturer facilities cover a range of compliance functions, including the systems and processes companies use to receive, investigate, document, and report adverse events from post-market surveillance. The inspection that produced the March 2026 warning letter identified deficiencies in Novo Nordisk’s adverse event handling and reporting compliance infrastructure.
Following a warning letter, manufacturers are typically required to respond with a corrective action plan addressing the identified violations within the timeframe specified by the agency. The FDA gave Novo Nordisk two weeks to provide its corrective response. The content of that response — and the FDA’s assessment of whether the corrective actions taken are adequate — will determine what, if any, further regulatory action follows. Warning letters are serious enforcement actions, but they do not automatically result in product recalls or market withdrawals. Ozempic and Wegovy remain FDA-approved and on the market.
Novo Nordisk’s Response
Novo Nordisk publicly acknowledged receipt of the FDA warning letter and stated that it is working to address the agency’s concerns. The company indicated that it takes its adverse event reporting obligations and post-approval safety monitoring responsibilities seriously and intends to provide a comprehensive response to the FDA within the required timeframe.
No further details about the specific corrective actions Novo Nordisk intends to take have been made public. The company has not disputed the underlying factual basis of the FDA’s findings in its public communications, nor has it characterized the FDA’s concerns as unfounded.
Why the Warning Letter Matters for GLP-1 Litigation
For attorneys and plaintiffs in the thousands of GLP-1 lawsuits currently consolidated in MDL 3094 and MDL 3163 in the Eastern District of Pennsylvania, the FDA warning letter is a significant evidentiary development. Its implications extend well beyond the three specific adverse events cited in the letter.
Evidence of Systemic Reporting Failures
A formal FDA finding that a pharmaceutical manufacturer was not meeting its 15-day expedited reporting obligations does not suggest an isolated administrative lapse. Post-market adverse event reporting is a core regulatory compliance function for any pharmaceutical company, staffed by dedicated regulatory affairs professionals operating within defined standard operating procedures. A finding of non-compliance suggests potential systemic failures in those processes — which, in turn, raises questions about the completeness and timeliness of the safety data that informed FDA label review decisions throughout the period of non-compliance.
The failure-to-warn theory at the center of GLP-1 litigation rests on the argument that Novo Nordisk knew — or had reason to know — about specific risks well before those risks appeared on the drug’s label. If the company was simultaneously failing to report adverse events to the FDA within required timeframes, plaintiffs’ attorneys can argue that the regulatory gap between known risk and disclosed warning was at least partly a function of the manufacturer’s own non-compliance with reporting obligations. Our FDA warning labels history page documents the full timeline of Ozempic label changes and what each update’s timing means for failure-to-warn claims.
Implications for the Adequacy of Post-Market Surveillance
The FDA’s post-market surveillance system — including the FAERS adverse event database and the mandatory expedited reporting requirements — functions as designed only when manufacturers submit reports promptly and completely. If Novo Nordisk was not meeting its reporting obligations, the FDA’s safety monitoring function may have been operating on an incomplete data set for a period that overlaps with the rapid expansion of GLP-1 prescribing. Label updates that might otherwise have occurred earlier — based on complete and timely adverse event data — may have been delayed as a result. That possibility is precisely the kind of argument plaintiffs’ counsel in MDL 3094 and MDL 3163 will develop through discovery and expert testimony.
Strengthening Discovery Arguments
In pharmaceutical MDL proceedings, plaintiffs’ counsel seek access to the manufacturer’s internal documents through discovery — including internal adverse event reports, safety memos, regulatory correspondence, and records of what the company’s pharmacovigilance team knew and when. The FDA warning letter provides a formal, publicly documented predicate for discovery requests into Novo Nordisk’s adverse event reporting systems, compliance history, and the specific incidents cited in the letter. For a full overview of how the litigation is structured and what plaintiffs are pursuing, see our current GLP-1 litigation status page.
Understanding Post-Market Adverse Event Reporting
To appreciate why the FDA’s warning letter is significant, it helps to understand how the post-market adverse event reporting system works and what it is designed to accomplish.
The Role of FAERS
The FDA Adverse Event Reporting System — FAERS — is the agency’s primary tool for collecting and analyzing safety information on approved drugs after they enter the market. It is a publicly accessible database populated by reports from three sources: patients and consumers who voluntarily report their own experiences, healthcare providers who report events they observe in clinical practice, and manufacturers who are legally required to submit reports of serious adverse events that come to their attention through any channel.
Manufacturer reports are subject to the most rigorous regulatory requirements. Unlike voluntary patient or provider reports, manufacturer expedited reports must be submitted within 15 days of the company becoming aware of a serious and unexpected adverse event. The completeness and timeliness of manufacturer submissions are therefore foundational to the reliability of the safety surveillance function. Patients, attorneys, and researchers can access FAERS data directly through the FDA’s public portal. See our FDA warning labels and FAERS overview for context on what the adverse event data for semaglutide shows and how it has been used in the litigation.
What Adverse Events Do and Do Not Establish
A fundamental principle of pharmacovigilance is that an adverse event report does not prove causation. FAERS is a signal detection system, not a causal analysis tool. When a patient who is taking Ozempic develops a gastrointestinal complication, becomes severely depressed, or dies, a report of that event in FAERS means only that the event occurred in a person who was taking the drug — not that the drug caused it. Regulators, researchers, and courts all recognize this distinction, and it is an important one for readers of this page to understand.
What FAERS data can establish, when analyzed systematically across large numbers of reports, is whether certain adverse events are occurring at rates that are disproportionate to what would be expected in a similar patient population not taking the drug — a statistical technique called disproportionality analysis. When that kind of signal is identified, it becomes the basis for further regulatory investigation, including label review and, potentially, required label updates. The system works as designed only when reports are submitted completely and on time.
Psychiatric Adverse Events and GLP-1 Drugs
The reference in the FDA warning letter to a suicide-related adverse event has drawn particular attention because psychiatric effects have been an area of regulatory scrutiny for GLP-1 drugs internationally, even without a definitive causal finding having been established. The FDA’s own FAERS database contains reports of depression, suicidal ideation, and mood disturbances in GLP-1 drug users, and international regulators — most notably the European Medicines Agency — have undertaken formal reviews of psychiatric safety signals associated with this drug class.
The EMA’s review, which was prompted in part by reports of suicidal ideation in GLP-1 drug users, ultimately concluded that available data did not establish a causal relationship between GLP-1 drugs and psychiatric outcomes — but the agency also noted the need for continued monitoring. In the United States, the FDA has similarly stated that it has not concluded that GLP-1 drugs cause psychiatric adverse events, while keeping the topic under ongoing post-market surveillance. The fact that a suicide-related report was among the adverse events Novo Nordisk allegedly failed to submit within the required 15-day window adds a specific dimension to the psychiatric safety question that is likely to attract attention in both regulatory and litigation contexts. For a full discussion of the psychiatric effects concern, see our Ozempic psychiatric effects page.
The Broader Regulatory Spotlight on GLP-1 Drugs
The March 2026 warning letter is not an isolated event. It is the most recent in a series of significant regulatory actions and developments that have placed GLP-1 drugs under intensifying scrutiny from multiple directions simultaneously. Understanding it in that context helps clarify its significance.
Regulatory actions and developments affecting GLP-1 drugs in the period leading up to and coinciding with the warning letter include:
- The January 2025 Ozempic label update — among the most substantive in the drug’s history — which added explicit pancreatitis language, a gastroparesis restriction, and new adverse reactions including acute kidney injury and alopecia
- The October 2025 label update further expanding gastrointestinal warnings to include intestinal obstruction, severe constipation, and fecal impaction
- The European Medicines Agency’s August 2024 directive requiring NAION vision loss to be added to GLP-1 drug labels in Europe — an action the FDA has not yet mirrored in the United States
- The WHO’s June 2025 global public health alert warning healthcare professionals about the NAION risk associated with semaglutide
- The establishment of MDL 3163 in December 2025 specifically for GLP-1 vision loss claims, reflecting the rapid growth of NAION litigation
- Ongoing FDA enforcement actions against compounded GLP-1 products and the proposed restriction of semaglutide from the 503B bulks list
Taken together, these developments describe a regulatory environment in which GLP-1 drugs — despite their undisputed therapeutic value — are subject to an unprecedented level of post-market safety monitoring and enforcement attention. The March 2026 warning letter is consistent with that pattern and adds a new dimension: not just what the label says about risk, but whether the manufacturer has been providing the FDA with the complete, timely data it needs to make those label decisions. For the full FDA label change history and its litigation significance, see our FDA warning labels and regulatory history page.
What This Means for Patients
Patients currently taking Ozempic, Wegovy, or other semaglutide-based medications do not need to discontinue their treatment based on the FDA warning letter. The letter addresses reporting compliance — it is not a safety recall, a market withdrawal, or a determination that these drugs are unsafe for their approved indications. Both Ozempic and Wegovy remain FDA-approved and on the market.
What the warning letter does mean, practically, is that the post-market safety monitoring system that patients rely on to generate timely label updates and safety communications may have been operating on incomplete data during the period in question. That is a systemic concern rather than an immediate clinical one — but it is a concern that patients and their physicians are entitled to factor into their treatment discussions.
For patients who have experienced serious adverse effects from GLP-1 medications — including gastroparesis, bowel obstruction, NAION vision loss, pancreatitis, or gallbladder disease — the warning letter may be relevant to the strength of their legal claims. The eligibility criteria for GLP-1 lawsuits, and how the warning letter fits into the failure-to-warn legal framework, are covered on our GLP-1 lawsuit eligibility page.
Key Takeaways
For patients, legal professionals, and others following GLP-1 regulatory developments, the following points summarize the significance of the March 2026 FDA warning letter:
- The FDA issued a formal warning letter to Novo Nordisk on March 5, 2026, alleging serious violations of federal adverse event reporting requirements for semaglutide products
- The letter was based on an inspection of a Novo Nordisk facility in New Jersey and cited failure to submit adverse event reports within the required 15-day window, including three reports involving patient deaths
- One of the cited reports involved a patient death by suicide; the FDA also alleged that Novo Nordisk failed to adequately investigate that event before the reporting window closed
- The FDA did not conclude that Ozempic or Wegovy caused any of the cited deaths; the violations are procedural, not findings of causation
- Novo Nordisk stated it is working to address the FDA’s concerns; the medications remain approved and on the market
- For GLP-1 litigation, the warning letter is significant new evidence: it raises questions about whether Novo Nordisk’s reporting failures compromised the FDA’s ability to identify safety signals and require timely label updates
- The letter strengthens discovery arguments in MDL 3094 and MDL 3163, supporting requests for internal adverse event documentation, pharmacovigilance records, and compliance history
Post-market safety reporting is not a bureaucratic formality. It is the primary mechanism through which regulators detect emerging risks in drugs used by millions of patients. When a manufacturer allegedly fails to meet those obligations — as the FDA contends Novo Nordisk did — the integrity of the entire post-approval safety system is placed in question. That is why this warning letter, whatever its ultimate regulatory consequences, is a significant moment in the GLP-1 story.